537 related articles for article (PubMed ID: 11312349)
1. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
[TBL] [Abstract][Full Text] [Related]
3. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
[TBL] [Abstract][Full Text] [Related]
4. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
6. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Ying C; De Clercq E; Nicholson W; Furman P; Neyts J
J Viral Hepat; 2000 Mar; 7(2):161-5. PubMed ID: 10760047
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
10. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance.
Zoulim F
Semin Liver Dis; 2002; 22 Suppl 1():23-31. PubMed ID: 12447726
[TBL] [Abstract][Full Text] [Related]
11. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
12. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
16. Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.
Iyer RP; Jin Y; Roland A; Morrey JD; Mounir S; Korba B
Antimicrob Agents Chemother; 2004 Jun; 48(6):2199-205. PubMed ID: 15155222
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
18. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
Ladner SK; Miller TJ; Otto MJ; King RW
Antivir Chem Chemother; 1998 Jan; 9(1):65-72. PubMed ID: 9875378
[TBL] [Abstract][Full Text] [Related]
19. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
Xiong X; Flores C; Yang H; Toole JJ; Gibbs CS
Hepatology; 1998 Dec; 28(6):1669-73. PubMed ID: 9828233
[TBL] [Abstract][Full Text] [Related]
20. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
